OCX
Price:
$2.885
Market Cap:
$48.57M
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Dete...[Read more]
Industry
Biotechnology
IPO Date
2015-12-30
Stock Exchange
NASDAQ
Ticker
OCX
According to OncoCyte Corporation’s latest financial reports and current stock price. The company's current PE Ratio is -0.67. This represents a change of -34.39% compared to the average of -1.02 of the last 4 quarters.
The mean historical PE Ratio of OncoCyte Corporation over the last ten years is -6.74. The current -0.67 PE Ratio has changed 893.43% with respect to the historical average. Over the past ten years (40 quarters), OCX's PE Ratio was at its highest in in the March 2023 quarter at 4.40. The PE Ratio was at its lowest in in the September 2014 quarter at -34.95.
Average
-6.74
Median
-5.20
Minimum
-16.75
Maximum
-0.48
Discovering the peaks and valleys of OncoCyte Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 55.90%
Maximum Annual PE Ratio = -0.48
Minimum Annual Increase = -83.91%
Minimum Annual PE Ratio = -16.75
Year | PE Ratio | Change |
---|---|---|
2023 | -0.69 | 42.17% |
2022 | -0.48 | -83.91% |
2021 | -3.01 | -42.42% |
2020 | -5.23 | 1.15% |
2019 | -5.17 | 55.90% |
2018 | -3.32 | -54.25% |
2017 | -7.25 | -56.73% |
2016 | -16.75 | 11.41% |
2015 | -15.03 | 42.88% |
2014 | -10.52 | -29.90% |
The current PE Ratio of OncoCyte Corporation (OCX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.39
5-year avg
-2.92
10-year avg
-6.74
OncoCyte Corporation’s PE Ratio is less than Burning Rock Biotech Limited (-0.36), greater than Neuronetics, Inc. (-1.00), greater than DarioHealth Corp. (-6.66), less than Genetron Holdings Limited (-0.63), greater than Sera Prognostics, Inc. (-8.21), greater than Olink Holding AB (publ) (-96.25), less than FONAR Corporation (6.11), greater than Castle Biosciences, Inc. (-303.67), greater than Exagen Inc. (-2.59), greater than Personalis, Inc. (-3.23), less than Interpace Biosciences, Inc. (3.81), greater than iSpecimen Inc. (-5.52), greater than Trinity Biotech plc (-0.72), less than Intelligent Bio Solutions Inc. (-0.22), greater than Biodesix, Inc. (-4.64), greater than Precipio, Inc. (-2.35), greater than ProPhase Labs, Inc. (-1.56), less than Sotera Health Company (111.75),
Company | PE Ratio | Market cap |
---|---|---|
-0.36 | $28.58M | |
-1.00 | $32.73M | |
-6.66 | $28.19M | |
-0.63 | $127.29M | |
-8.21 | $254.75M | |
-96.25 | $3.24B | |
6.11 | $92.52M | |
-303.67 | $944.16M | |
-2.59 | $42.94M | |
-3.23 | $266.17M | |
3.81 | $10.75M | |
-5.52 | $4.12M | |
-0.72 | $19.22M | |
-0.22 | $5.98M | |
-4.64 | $201.80M | |
-2.35 | $9.10M | |
-1.56 | $41.40M | |
111.75 | $4.49B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like OncoCyte Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like OncoCyte Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is OncoCyte Corporation's PE Ratio?
How is the PE Ratio calculated for OncoCyte Corporation (OCX)?
What is the highest PE Ratio for OncoCyte Corporation (OCX)?
What is the 3-year average PE Ratio for OncoCyte Corporation (OCX)?
What is the 5-year average PE Ratio for OncoCyte Corporation (OCX)?
How does the current PE Ratio for OncoCyte Corporation (OCX) compare to its historical average?